about
Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila modelAbrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.Memo mediates ErbB2-driven cell motility.mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.Functional relevance of the histone gammaH2Ax in the response to DNA damaging agents.Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouseA modular lentiviral and retroviral construction system to rapidly generate vectors for gene expression and gene knockdown in vitro and in vivoRAS transformation requires CUX1-dependent repair of oxidative DNA damage.β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomasB-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancerThe Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesisHematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720.Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.The inhibitor of kappa B kinase-epsilon regulates MMP-3 expression levels and can promote lung metastasis.Braf(V600E) cooperates with Pten loss to induce metastatic melanomaThe c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation.Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins.Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor.
P50
Q28568629-C8293739-4BD6-4D68-9A75-F1B7A26FA37BQ34253185-85BB2E2D-E564-4F16-9FFA-0C33B100DD3EQ34322240-8DA4D76C-BBC0-4BC6-91D7-494A9BF4F7CCQ34965452-EC45823E-742E-485C-A078-7BAA9F03EE5DQ35008272-EACB81CE-1184-44D3-9A7B-D96F49384B7BQ35022217-4F78557E-8D3C-43D7-9EC5-62EFB6D6F40FQ35022698-86894CC4-9E76-4101-AE5D-AE176541739EQ35117739-E4FC4E9D-53A7-4CD0-BB54-F2118D8139D3Q35621787-6FF7D1EA-15C8-4074-96D7-123737B8617BQ36243554-42E1D4D8-691B-4F33-9922-49B682BC4D3CQ36601812-ECAEA1F6-8BC0-4274-B6CF-0665D2353C51Q37407268-61A26E7C-F8BD-446D-8310-75F9076FBB72Q37525082-6B48991F-0A1B-45AA-A055-364397398577Q37536351-49AC88FF-0266-44F1-9F58-FA809B8362B3Q39873596-3939F6D9-256A-41D0-A334-2B26752AE68CQ40371716-C19F97ED-445D-4870-896D-1260F4CA6D35Q40786730-EA356BA9-C796-4803-9738-0720CC54AA6EQ43583406-B288F92B-D771-4D48-8796-9A008A1E42F2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Dankort
@ast
David Dankort
@en
David Dankort
@es
David Dankort
@nl
David Dankort
@sl
type
label
David Dankort
@ast
David Dankort
@en
David Dankort
@es
David Dankort
@nl
David Dankort
@sl
prefLabel
David Dankort
@ast
David Dankort
@en
David Dankort
@es
David Dankort
@nl
David Dankort
@sl
P106
P21
P31
P496
0000-0002-5862-6829